A large review found diagnosis-dependent associations between psychotropic treatment and suicide-related outcomes, including concerning benzodiazepine signals.
The systematic review included 48 independent observational studies involving more than six million people with specified psychiatric diagnoses. It evaluated suicide mortality and suicide attempts or self-harm, with comparisons between treated and untreated people or between prescription and nonprescription periods within individuals.
Benzodiazepines were associated with higher suicide mortality in most diagnostic categories, with depression an exception in the reported synthesis. The findings should therefore not be flattened into an identical effect across all patients or diagnoses.
Anxiety severity, acute crises, substance use, sleep disturbance, and treatment selection can affect both prescribing and suicide risk. The authors explicitly cautioned that the results are not causal. Even a carefully conducted observational synthesis inherits the limitations of the underlying exposure and outcome records.
For review of an individual death, reconstruct indication, timing, actual use, other medicines, and the clinical state before treatment. A population association does not establish intent, mechanism, or causation in that case. The paper supports careful risk assessment and better research, while leaving substantial uncertainty about medication-specific effects and the reasons treatment was initiated.
Original analysis of the supplied journal article, identified as PMC12945523.